The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
you are missing, poor Chippy? Oh dear, oh dear..doesn't look as though you are very good at investing, does it?
Nothing I post is investment advice. I am long SAG
Being one of the lucky medium/long term owners (bought Generics under 20p - punt on steep discount to TNW and hope of turnaround), I am still hopeful of further re-rating. NAV is reported at 69p but is surely higher since rental on part of property seems to yield 10% on whole b/s value (I haven't noticed any recent revaluation of property) and EV/EBIT seems attractive especially if you (1) disaggregate EBIT into consultancy (riskier) and property profitability and (2) factor in tax shield of prior year tax losses. Interested in others' views on CEO departure and new strategic push for "organic business growth opps"
im in the normal boozer tonight
The research and development consultancy, Sagentia, has issued a warning on 2012 revenues after a big project with a north American medical start-up was suspended.
The group's update maintains: "Actions have been taken to mitigate this event and these have been effective in enhancing operating margins. As a result for the full year, while revenue will be lower than last year, profit is anticipated to be in line with the Board's expectations."
The research and development consultancy, Sagentia, has issued a warning on 2012 revenues after a big project with a north American medical start-up was suspended. Sagentia says the suspension will see revenues in the first half of 2012 coming in lower than the second six months of 2011. The group also expects revenues for full year 2012 to be below 2011.
AGM Trading Update Sagentia Group plc (AIM:SAG), the international technology company which provides outsourced R&D consultancy services, provides the following trading update ahead of the Company's Annual General Meeting this morning. The Group's preliminary results for 2011 were released on 5 March 2012 in which the Group reported that satisfactory progress had been made in consolidating the turnaround achieved in 2010, but that the Group had experienced some effects from the deterioration in the macro-economic environment in the second half of the year. Since the start of the current year the Group has seen some early signs of an improvement in the general economic situation and renewed interest from the Industrial sector in particular. Unfortunately, a large project with a North American start-up in the Medical sector has been suspended which will result in Group revenue in the first half of 2012 being lower than the revenue reported in the second half of 2011, despite the underlying business continuing to grow. Actions have been taken to mitigate this event and these have been effective in enhancing operating margins. As a result for the full year, while revenue will be lower than last year, profit is anticipated to be in line with the Board's expectations. With a strong balance sheet the Board continues to evaluate potential merger and acquisition opportunities, although remains prudent in this process.
http://www.investegate.co.uk/Article.aspx?id=201204160700213525B
Good day today - should see this tick up to £1 plus now.
Great results today - confirmed that cash and property now 70p plus of share price. The tender offer, if people take it up will be earnings enhancing for the balance of shareholders which is also good news. Personally, I dont see why many would sell out for 80p - expect to see earnings/broker upgrades for next year.
AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2011 Sagentia Group plc is an international technology consulting company providing outsourced R&D consultancy services from market analysis, through product development to transfer-to-manufacturing for the medical and commercial sectors. Summary: · Revenue growth of 13% to £23.6 million (2010: £20.8 million). · Operating profit increased by 54%. Profit before tax increased by 55%. · Profitability in-line with upgraded market expectations. · Operating profit of £3.9 million (2010: £2.5 million). · PBT from continuing operations at £3.3 million (2010: £2.2 million). · Net income from continuing operations of £3.3 million (2010: £2.3 million). · Diluted EPS from continuing operations of 7.3p (2010: 6.8p). · Strong balance sheet with gross cash balance at 31 December 2011 of £21.2 million (2010: £16.4 million) and net funds of £14.1 million (2010: £8.6 million). · Proposed tender offer to return up to £8 million to shareholders at 80 pence per share.
http://www.investegate.co.uk/Article.aspx?id=201203050700136391Y
Sagentia - Buy at 91p from James Faulkner of WatsHot.com A bargain? Shareholder funds as at 30th June 2011 stood at £24.7 million (compared to a market cap of £38 million) with c.£14 million in property assets and £10.1 million in net cash. The business itself, which generated £3.4 million in operating cashflow during 2010, is in there for very little. I would suggest that one cannot go far wrong paying around 3 times cashflow for such an innovative business with great growth prospects and an international outlook (77% of sales are now derived from overseas). Looking forward, Sagentia "continues to evaluate acquisition opportunities to accelerate the growth of the Group" and it remains "cautiously optimistic about prospects for the year as a whole... providing the confidence to invest in the future development of Sagentia." Any M&A activity should be positive for the shares, especially given the track record of Chairman Martyn Ratcliffe (who owns a 29.9% stake). This is solid value. Buy.
Contract Win Sagentia Group plc (AIM:SAG), the outsource technology R&D company, has signed a multi-year contract with a major US consumer company to provide outsourced R&D services, including new product development. The value of the contract is approximately US$10 million over the initial term of three years and follows a number of successful projects that Sagentia has undertaken for the client in the current year. Over the past 18 months, Sagentia has been evolving from a project-oriented consultancy to becoming a strategic partner with its major customers. This strategy, which has also been successful in the Medical sector, improves forward demand visibility, resource scheduling and reduces the cost of sale, enabling Sagentia to be more competitive in the market and provide even better value and service to its strategic customers. This new contract is a major progression of this strategy within the Group's Consumer sector.
http://www.investegate.co.uk/Article.aspx?id=201109290730011706P
T.C - Indeed it was a fine day for SAG - but Im afraid I wasnt part of it ! Looks good though
Shares in Sagentia (SAG) swelled 9p to 86.5p on news profit in the first six-months of the year will materially exceed its expectations. The technology consulting company said that “with high utilisation, tight cost control and a lower risk consultancy operating model now established”, its operating model has continued to improve. Looking ahead, the group added that it is expecting “another good year”.
Yes so you are here as well mulled, but not since 16/5/11!! Todays RNS look promising I think.http://www.stockopedia.co.uk/share-prices/sagentia-ag-LON:SAG/news/rns//110707sag9131j.htm?title=trading-update
AGM Trading Update Sagentia Group plc (AIM:SAG), the international technology consulting company which provides outsourced R&D consultancy services, reports the following trading update ahead of the Company's Annual General Meeting this morning. The Group's preliminary results for 2010 were released on 28 February 2011 when a strong turnaround in operating performance was reported. Since the start of the current year, the Group has continued to perform well, with profit at the end of April materially ahead of the Board's expectations. The Medical Sector has performed particularly strongly in the first part of the year. At 30 April 2011, the Group's gross cash was £17.2 million with net cash of £9.5 million. While the market characteristics provide limited forward visibility, the actions taken in 2010 have significantly improved the Group's controllable risk profile. As a result, and combined with the strong start to the year, the Board is cautiously optimistic for the year ahead. With a strong balance sheet, the Board continues to evaluate potential merger and acquisition opportunities, although remains prudent in this
ALOO
Sagentia beats expectations but warns on demand Date: Monday 28 Feb 2011 LONDON (ShareCast) - Sagentia’s profits for the year to 31 December beat expectations, but the technology and product development consultant sounded a cautious note on future trading, saying demand is unpredictable. The company moved to a pre-tax profit of £2.2m against a loss of £3.5m the previous year, even as revenues fell to £20.8m from £23.4m. Revenue for 2009 included £6.3m from a project that was spun out of the group. “As a project-based consultancy, forward visibility is typically limited and, although the group benefits from sector and geographical diversification, future demand is not predictable,” the company said. “The board therefore remains prudent in managing the business.”
Arbuthnot retained its "strong buy" recommendation and 85p target price for technology consultant Sagentia Group (SAG). Commenting on the group ahead of finals at the end of the month, the broker said the business's cash position provides a "strong" underpinning to the share price and means the firm is well positioned to participate in M&A. Moreover, with trading momentum remaining strong, Arbuthnot is hopeful that the upgrade trend achieved last year by the new management team will continue. The shares fell 4.5p to 72.5p.
There is no need to ramp a share when it produces results like these. Wow!